Royal Biologics
-
Biologics
Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE™ PRFM
BIOINCYTE™ is a Next-Generation Autologous Fibrin and Platelet System HACKENSACK, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) — Royal Biologics, a…
Read More » -
Biologics
Royal Biologics Completes 100th Cryo Cord™ Case, Successfully Enrolls First Patient Into Diabetic Foot Ulcer Study
HACKENSACK, N.J., September 18, 2020 (Newswire.com) – Royal Biologics, an ortho-biologics company specializing in the research and advancement of novel ortho-biologics…
Read More » -
Biologics
Royal Biologics Announces The Launch of CRYO-CORD™ The First NON-DMSO Viable Umbilical Cord Graft
–Debuts at the NY20 Foundation for Podiatric Medicine Meeting– HACKENSACK, N.J., January 21, 2020 —Royal Biologics, an ortho-biologics company specializing…
Read More » -
Biologics
Royal Biologics announces the launch of MAGNUS, a DMSO-free viable cellular bone allograft
JANUARY 08, 2020 Royal Biologics, an ortho-biologics company specializing in the research and advancement of regenerative cellular therapy and novel…
Read More » -
Biologics
Royal Biologics announces the U.S. commercial launch of Maxx-Ultra Cord
Royal Biologics, a leading manufacturer and distributor of orthobiologic and regenerative medicine solutions today has announced the U.S. commercial launch…
Read More » -
Biologics
Granite Creek Capital Partners, L.L.C. Announces an Investment in Royal Biologics
CHICAGO and JERSEY CITY, N.J., June 27, 2019 — Granite Creek Capital Partners, L.L.C., a private investment firm that partners…
Read More »